Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion ...

Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative acquisition, and it projects Seagen to contribute $10 billion in sales by 2030.

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...